TG THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.3 USD | -3.49% |
|
-2.45% | -4.57% |
| 05-01 | Wall Street Set to Open Lower Ahead of Fed Rate Decision; Private Employment Figures Top Forecasts | MT |
| 05-01 | Transcript : TG Therapeutics, Inc., Q1 2024 Earnings Call, May 01, 2024 |
| Sales 2024 * | 309M 421M | Sales 2025 * | 472M 644M | Capitalization | 2.33B 3.18B |
|---|---|---|---|---|---|
| Net income 2024 * | -3M -4.09M | Net income 2025 * | 101M 138M | EV / Sales 2024 * | 7.49 x |
| Net cash position 2024 * | 20.93M 28.52M | Net cash position 2025 * | 113M 153M | EV / Sales 2025 * | 4.7 x |
| P/E ratio 2024 * |
-741
x | P/E ratio 2025 * |
25.2
x | Employees | 284 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.42% |
More Fundamentals
* Assessed data
More news
Latest transcript on TG Therapeutics, Inc.
More recommendations
More press releases
| 1 day | -3.49% | ||
| 1 week | -2.45% | ||
| 1 month | -0.73% | ||
| 3 months | -9.24% | ||
| 6 months | +17.86% | ||
| Current year | -4.57% |
1 week
16.23
17.15
1 month
15.7618.41
Current year
12.8422.67
1 year
6.4629.32
3 years
3.4841.00
5 years
3.4856.74
10 years
3.3256.74
| Managers | Title | Age | Since |
|---|---|---|---|
Michael Weiss
CEO | Chief Executive Officer | 58 | 93-05-17 |
Sean Power
DFI | Director of Finance/CFO | 42 | 11-12-28 |
Jenna A. Bosco
IRC | Investor Relations Contact | - | 11-11-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Michael Weiss
CEO | Chief Executive Officer | 58 | 93-05-17 |
Laurence Charney
BRD | Director/Board Member | 76 | 12-02-29 |
Kenneth Hoberman
BRD | Director/Board Member | 59 | 14-12-14 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.08% | 2 M€ | -.--% | ||
| 0.07% | 1,487 M€ | +7.77% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 16.3 | -3.49% | 1,946,007 |
| 24-05-30 | 16.89 | +3.24% | 1,768,762 |
| 24-05-29 | 16.36 | -2.91% | 1,594,608 |
| 24-05-28 | 16.85 | +0.84% | 3,210,981 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm
More quotes
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Brutonâs tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.
Calendar
2024-06-14
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
16.3
USD
Average target price
31.5
USD
Spread / Average Target
+93.25%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -4.57% | 2.33B | |
| +43.36% | 54.63B | |
| -5.31% | 39.92B | |
| +14.75% | 26.86B | |
| -12.56% | 26.22B | |
| -22.45% | 18.78B | |
| +25.12% | 12.21B | |
| +0.04% | 12.16B | |
| +26.04% | 11.94B | |
| -11.83% | 10.74B |
- Stock Market
- Equities
- TGTX Stock
